30 June, 2022

BioChimPharm at the United Nations annual meeting
Concluding remarks of Rati Golijashvili, General Manager of BioChimPharm at the United Nations annual meeting, on the growing, global threat of antibiotic resistance (AMR) and the importance of Phage Therapy as the only viable alternative to antibiotic therapy nowadays.

General Manager of BioChimPharm took part in the United Nations 5th Annual Conference, also known as “Micro, Small, and Medium-sized Enterprises Day” on 27 June 2022

 Round table discussions were held by entrepreneurs from around the globe, to discuss the challenges of triple threats and impacts on business of Covid 19, conflict in Ukraine and climate change, which world currently faces.

30 June, 2022

EU-Georgia Business Forum 2022

On June 21 the European Business Association Georgia (EBA), with the support of the European Union organized the “EU-Georgia Business Forum 2022” in Sheraton Grand Tbilisi Metechi Palace

BioChimPharm (Phage Factory) was invited and presented as a partner of the European Business Association Georgia.

Rati Golijashvili, General manager of BioChimPharm, participated in panel discussions and shared his experience on challenges of the EU pharmaceutical manufacturing standards (GMP) compliance process, EU support, export opportunities for Georgian businesses to EU 500 million market and about Georgia, destined to be the part of the European Family. Last but not least, on advantages of Bacteriophages and its significance for Georgia and the whole world in fight against antibiotic resistance.

The forum was attended by over 300 people, including the EU Ambassador to Georgia Carl Hartzell, representatives of the Georgian Parliament, Government, Business Support Organizations, European Businesses from different sectors, Diplomatic Corps, International Organizations and Financial Institutions.

Phagyo,Phage,Phage TherapyPhagyo,Phage,Phage Therapy
Phagyo,Phage,Phage TherapyPhagyo,Phage,Phage Therapy
Phagyo,Phage,Phage TherapyPhagyo,Phage,Phage Therapy Phagyo,Phage,Phage TherapyPhagyo,Phage,Phage Therapy Phagyo,Phage,Phage Therapy

24 June, 2022

What is Phage therapy?

Bacteriophages (Phages) are microorganisms that target and kill specific bacteria. Phage therapy is effectively used to treat and prevent bacterial infections (including antibiotic resistant infections) by killing harmful bacteria that cause illnesses, while at the same time not affecting beneficial bacteria and microbiome of the human body.. Substitution of irrational use of antibiotics, which fuels development of the resistance (bacteria becomes resistant to certain antibiotics) is one of the greatest challenges for the society and security in terms of the emerging global threat of antibiotic resistance. Phage therapy is the only viable alternative to antibiotic therapy nowadays. Using phage biodiversity and advanced technologies  it is becoming increasingly accessible to discover new phages and develop highly effective bacteriophage based medicines, year by year. Dozens of phage preparations have commercially been and are available for more than 50 years.

Phage therapy has been  successfully used to treat patients with severe, incurable infections as well as those who have developed resistance to antibiotics. A growing number of successful cases give patients, suffering from resistant infections, a hope that antibiotics can be replaced by alternative treatments such as bacteriophages. For decades, Phages have been the subject of intensive scientific investigation, which has led to astonishing results:

• Phages can be used successfully in patients whose antibiotic treatment has failed;

• Scientists have a large documentary material based on multiple investigations;

• Technological improvements have increased the number of phages that can be used to develop new medicines.

What is Phage Therapy?

Phage therapy is a medical practice of applying bacteriophages and bacteriophage preparations for treatment and prevention of different chronic, severe infections caused by harmful (pathogenic) bacteria such as Staphylococcus (MRSA), E.Coli, Pseudomonas aeruginosa, Enterrococcus, Salmonella, Streptococcus (VRE), Proteus, Shigella, C. diff, Enterobacteriaceae, Acinetobacter and their combinations.Phage preparations are effectively used in medicine as a treatment for purulent-inflammatory infections, Bacterial infections of the upper and lower respiratory tract, gastrointestinal tract infections, in urology and infections of urogenital system, purulent-inflammatory neonatal infections, prosthetic joint infections and etc. caused by the above mentioned pathogenic bacteria. . Phages are also used to treat patients suffering from incurable multi-drug resistant infections.

Advantages of Phage therapy:

  • Phages selectively target and destroy only the disease-causing bacteria, including antibiotic resistant ones;
  •  Unlike antibiotics, phages do not affect and damage beneficial microbiome of the human body;
  •  Phages are used for treatment as well as for prevention of life-threatening infections


Phagyo® is a phage preparation and over the counter medicine that is one of the mostly used pharmaceutical product in Georgia and in the world of phage therapy. The phage preparation is produced by JSC BioChimPharm, the world leader in R&D and manufacturing of phage preparations with over 100 years of technological tradition and know-how.

Phagyo® used for treatment and prevention of bacterial purulent-inflammatory infections:

  • Bacterial infections of the upper and lower respiratory tract (inflammation of the sinuses, otitis media, tonsillitis, pharyngitis, laryngitis, tracheitis, bronchitis, pneumonia, pleuritis);
  • gastroenterology (enterocolitis, cholecystitis, dysbiosis);
  • in urology (urethritis, cystitis, pyelonephritis) ;
  • purulent-inflammatory neonatal infections (omphalitis, pyoderma, conjunctivitis, sepsis).

Due to its unique natural characteristics, Phagyo® can be used in adults, children, newborn babies, during pregnancy and lactation, as well as in all vulnerable groups of patients. The medicine has no side effects, does not contain flavorings and colorings, the components of the medicine are not genetically modified organisms. This is what ensures Phagyo®s unprecedented level of safety for any antimicrobial. One 20 ml vial of the medicine contains over10 million specially selected phages, which determines its quality and effectiveness.


13 June, 2022

What is a phage?

“Bacteriophage”, abbreviated as “phage”, means the absorber of bacteria. This word is made up from two Greek words: bacterium (which means “sticks”) and phagein which means (absorption).

Phages, the most common microorganisms on Earth, are invisible to the human eye. Phages can be found on the ground, in the water, on our skin, and inside our bodies. Not many people know, that humans absorb Millions of phages every day from food and water.


Bacteriophages have been given a great mission by nature: they must protect the earth from the overgrowth of bacteria and maintain the natural balance of life on the planet. In every 48 hours half of bacteria are eliminated by phages in the oceans.


The phage specifically destroys only its respective bacteria. Phages cannot harm human, animal or plant cells, which ensures  unprecedented levels of safety for any antimicrobial solution.

10 June, 2022

Phage Therapy VS Antibiotic Therapy – A special medicine that the world is looking for may be a phage therapy

Ivane Chkhaidze, the clinical director of the Iashvili Central Children’s Hospital, was contacted by colleagues from the Netherlands 3 years ago and asked for information about bacteriophages. This fact is another proof that the bacteriophages, discovered by Georgian and French scientists a century ago, are a well-deserved substitute for antibiotics in modern medicine. Antibiotic resistance is recognized by the World Health Organization (WHO) as a global problem threatening humanity. Antibiotic resistance is one of the main challenges of modernity, and at the same time, there is medicine being produced in Georgia that can effectively compete with antibiotics.

We talked to Ivane Chkhaidze, the clinical director of Iashvili Hospital, about the problems caused by antibiotic resistance, phage therapy, and “Phagyo”.

When did medicine start using antibiotics?

 The first antibiotic used in medicine was penicillin. It was discovered by Alexander Fleming in 1928 and was first used against infectious diseases in 1942. Medical Scientists thought that infectious diseases were practically defeated by the invention of antibiotics. In the early stages, it was indeed so, doctors believed that the appropriate antibiotic could be found for any infection in the human body. Antibiotics worked effectively and there was a vast choice of them. For example, in 1983-92, the US Food and Drug Administration (FDA) allowed 30 new antibiotics for clinical use, but none of the antibiotics were allowed since 2010! The problem of antibiotic resistance was added to the above-mentioned reasons and the reality changed so that the usage of antibiotics was reconsidered.

What caused the change in attitude towards antibiotics?

It turned out that there are some bacteria against which the antibiotic is powerless. The arsenal of different groups or combined antibiotics has been exhausted. Therefore, medicine faces a big dilemma. It is known that there are bacteria in the human body, but modern medicine doesn’t have the resources to fight them. The last new generation antibiotic, the fifth-generation cephalosporin, was delivered into clinical practice in 2010, which means that if we had dozens of new antibiotics in the 70s and 80s, it’s been 9 years since modern medicine does not have a new antibiotic to fight infections.

 What became the cause of antibiotic resistance?

There are many reasons. One of the main causes of antibiotic resistance is its inappropriate use. Failure to complete the course of antibiotics prescribed to the patient by the doctor, selection of the wrong dose, usage of antibiotics in agriculture, and several other reasons exist which promote the development of resistant forms. This is a multifactorial problem.

One of the causes of this problem is the antibiotic’s working mechanism. It eliminates not only the specific bacteria that cause the disease, but also all the bacteria in the body. In general, there are dangerous bacteria, as well as bacteria that are necessary for the body, and we call them “friendly” bacteria. When treated with antibiotics, not only the disease-causing – dangerous bacteria are eliminated in the body, but also the “friendly” bacteria.


In addition, there are antibiotics with a narrow and wide range of action areas. In this regard, a wide range of Medicines are especially dangerous, they destroy more bacteria and damage the useful microflora. For example, during pneumonia, we prescribe the medicine, that we need to fight against bacteria that cause pneumonia, but at the same time, it fights dozens of others that are not the reason for pneumonia. This is a negative side of antibiotics and one of the reasons for the development of its resistance.

How long can antibiotic resistance develop?

There is no specific time, even though this process has been greatly accelerated. For example, after the introduction of penicillin into clinical practice in 1942, it took 24 years to develop resistance to it, and the resistance to daptomycin developed in one year – started in 2003, resistance developed in 2004. so, we can say that finally all of the bacteria become resistant.

 What is the solution, what does world medicine have to do to solve the problem?

Bacteriophage (“bacteriophage” – bacteria absorber) was discovered in 1917 by a French scientist, Felix D. Erle, but the use of bacteriophage in clinical treatment dates back to the 1920s, thanks to him and Georgian scientist Giorgi Eliava. Bacteriophage could be one of the solutions to the resistance problem. In the previous century, there was no need for it because there was an antibiotic that “worked” quite well against the bacteria. However, when the issue of antibiotic resistance arose, many people remembered the bacteriophage. The medication was formerly only used in Georgia and post-Soviet countries. Because the bacteriophage was confined to Russian-language literature, it was mostly unknown around the world. However, after the aggravation of the antibiotic resistance problem, was started a new stage in the history of bacteriophage. After this, not only Georgians but also foreign doctors are particularly active. Over the last 10 years, up to 100 English-language papers have been published about this medicine.

To be more specific, what is the principle of bacteriophage?

Bacteriophage intentionally destroys only disease-causing bacteria in the body, without any negative side effects. The main difference between an antibiotic is, that the antibiotic affects all the bacteria in the body, while the bacteriophage is more specific.

Comparing the annotation of phage and antibiotics, we can easily understand the main differences between their actions. Phage affects 5 types of bacteria. These are Streptococcus, Staphylococcus, E.coli, Proteus, and Pseudomonas. While in the narrowest-spectrum antibiotic list are these five bacteria and more dozens of bacteria. The same is effects – the wider the range of antibiotic action, the longer the list of side effects. Physiotherapy has no side effects. We should not forget the fact that the phage does not create a resistant microflora.


Is phage therapy prescribed before the development of inflammation or directly during inflammation?

During inflammation, phages can be treated directly, but the underlying cause must be identified. It takes some courage to fight inflammation without antibiotics, but if the doctor is convinced that there it is one of the five leading bacteria, then he should use phage therapy.

How often do you use phage therapy?

“Phagyo” (Georgian medicine) is used for phage therapy in Georgia. It has proven many times its effectiveness in practice. I have one special story about this medicine. 3 years ago, I was contacted by colleagues from the Netherlands about a bacteriophage produced in Georgia. They had a patient with a congenital disease – cystic fibrosis, which is characterized by the presence of recurrent, bacterial inflammatory processes in the respiratory system. The patient was 18 years old and he already had resistance to antibiotics and his life was in danger. After a course of phage therapy with this patient gave us better results than antibiotic therapy.

After this I am interested in phage therapy, it turned out that there are several recent interesting studies in English and it is considered one of the alternatives to antibiotic therapy.

6 May, 2022


Statement on the general meeting of JSC “BiochimPharm”

according to the Law of Georgia on Entrepreneurs, the Supervisory Board of JSC “BiochimPharm” convenes another general meeting of shareholders of JSC, which will be held on May 30, 2022, at 12:00 a.m. Address: st. Tbilisi, Gotua st. 8. Form of voting: Open form of voting of the attending shareholders – by raising their hands.


Meeting agenda:


  1. Annual report.
  2. Approval of the report of the Supervisory Board.
  3. Report on the economic situation.
  4. Proposal on net profit distribution.
  5. Approval of the director’s report.



The shareholder can check the right to participate in the meeting (accounting day) from 10 May to 20 May 2022 from 10 May to 20 May 2022. The shareholder must have an ID card. Address: Independent Registrar JSC “United Registrar of Securities of Georgia” (License N 70006; I. Chavchavadze Avenue N74a, 0162 Tbilisi, Georgia, telephone number: 2225351).


The shareholder who had the right of ownership for the accounting day of the general meeting has the right to participate and vote in the general meeting. Representation is allowed on the basis of a notarized power of attorney.

For detailed information regarding the meeting and recommendations on the agenda, shareholders can apply to the Supervisory Board of JSC “BiochimPharm”.



Director of JSC “BiochimPharm”
A. Gholijashvili


13 September, 2019

Georgian BioChimPharm wins grant to further develop natural alternative to antibiotics for livestock breeding

Georgian biotech company BioChimPharm has won a grant from the Georgian Innovation and Technology Agency for its innovative veterinary antimicrobial product –  PowerPhage.

PowerPhage is the world’s first natural antimicrobial effective in fighting harmful bacteria such as Salmonella, E. coli and Shigella.

The product aims to provide alternatives to the use of antibiotics in poultry and livestock production and fight against the problem of antibiotic resistance.

PowerPhage can replace antibiotics on chicken and livestock farms, the company says.

Unlike other antimicrobials such as antibiotics, phages selectively eliminate disease-causing bacteria without harming the beneficial microflora of the organism.

”PowerPhage works against antibiotic resistant bacteria and inhibits the spread of antibiotic resistance. It is 100% natural, non-toxic and biodegradable”, the head of the innovation and business development department at BioChimPharm Rati Golijashvili says.

PowerPhage is still in the final stages of development, but will go public shortly.

The company BioChimPharm (BCP) has more than 80 years of experience in developing and manufacturing phage-based, alternative antibiotic remedies. The company is engaged in the development and production of a sustainable alternative to antibiotics.

The development and research of the phage-based therapy in Georgia is connected with the Georgian physician, bacteriologist and phage researcher George Eliava (1892-1937). Together with French-Canadian scientist Felic D’Herelle, who first discovered bacteriophages, Eliava had founded a bacteriological institute in Tbilisi in 1923.  Giorgi Eliava was executed during the Stalin’s red terror in 1937.

24 May, 2017

News 2

What is Lorem Ipsum?

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Why do we use it?

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout. The point of using Lorem Ipsum is that it has a more-or-less normal distribution of letters, as opposed to using ‘Content here, content here’, making it look like readable English. Many desktop publishing packages and web page editors now use Lorem Ipsum as their default model text, and a search for ‘lorem ipsum’ will uncover many web sites still in their infancy. Various versions have evolved over the years, sometimes by accident, sometimes on purpose (injected humour and the like).


Where does it come from?

Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source. Lorem Ipsum comes from sections 1.10.32 and 1.10.33 of “de Finibus Bonorum et Malorum” (The Extremes of Good and Evil) by Cicero, written in 45 BC. This book is a treatise on the theory of ethics, very popular during the Renaissance. The first line of Lorem Ipsum, “Lorem ipsum dolor sit amet..”, comes from a line in section 1.10.32.

The standard chunk of Lorem Ipsum used since the 1500s is reproduced below for those interested. Sections 1.10.32 and 1.10.33 from “de Finibus Bonorum et Malorum” by Cicero are also reproduced in their exact original form, accompanied by English versions from the 1914 translation by H. Rackham.